Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-05-17
2010-06-08
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07732467
ABSTRACT:
The present invention provides methods for reducing β-amyloid deposition, β-amyloid neurotoxicity and microgliosis in animals or humans afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the dihydropyridine calcium channel antagonist, nilvadipine. The present invention also provides methods for diagnosing cerebral amyloidogenic diseases in animals or humans. Further provided are methods for reducing the risk of β-amyloid deposition, β-amyloid neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering nilvadipine immediately after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter. Finally, methods are provided for treating transplantable neuronal stem cells by administering nilvadipine to the neuronal stem cells prior to transplantation in the central nervous system of an animal or human afflicted with a cerebral amyloidogenic disease, such as AD.
REFERENCES:
patent: 4338322 (1982-07-01), Sato et al.
patent: 4654206 (1987-03-01), Okuda et al.
patent: 4820720 (1989-04-01), Sanders et al.
patent: 4859688 (1989-08-01), Yamaguchi et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5045553 (1991-09-01), Ueda et al.
patent: 5053419 (1991-10-01), Lipton et al.
patent: 5114946 (1992-05-01), Lawter et al.
patent: 5160734 (1992-11-01), Ganesan et al.
patent: 5340591 (1994-08-01), Nakano et al.
patent: 6271259 (2001-08-01), Kakuda et al.
patent: 6294544 (2001-09-01), Araie et al.
patent: 6420405 (2002-07-01), Inada et al.
patent: 6818200 (2004-11-01), Foster et al.
patent: 2001/0011098 (2001-08-01), Inada et al.
patent: 2002/0042405 (2002-04-01), Schuh
patent: 2002/0094995 (2002-07-01), Foster et al.
patent: 2003/0013699 (2003-01-01), Davis et al.
patent: 2003/0044845 (2003-03-01), Jenkins et al.
patent: 2003/0055027 (2003-03-01), Schun
patent: 2003/0139801 (2003-07-01), Sirhan et al.
patent: 2004/0063730 (2004-04-01), Eggenweiler et al.
patent: 2004/0072846 (2004-04-01), Eggenweiler et al.
patent: 2004/0101517 (2004-05-01), Bolton et al.
patent: 2005/0031651 (2005-02-01), Gervais et al.
patent: 4141646 (1993-06-01), None
patent: 42 29 805 (1994-03-01), None
patent: 0 294 601 (1988-12-01), None
patent: 0 301 133 (1989-02-01), None
patent: 0 317 780 (1989-05-01), None
patent: 0 628 313 (1994-12-01), None
patent: 1 260 232 (2002-11-01), None
patent: 1 285 655 (2003-02-01), None
patent: 61129140 (1986-06-01), None
patent: 03117658 (1990-05-01), None
patent: 03099061 (1991-04-01), None
patent: 03123730 (1991-05-01), None
patent: 05139974 (1993-06-01), None
patent: 2001335483 (2001-12-01), None
patent: 2002087959 (2002-03-01), None
patent: 2002097140 (2002-04-01), None
patent: 2003146878 (2003-05-01), None
patent: 03470096 (2003-11-01), None
patent: 2004002460 (2004-01-01), None
patent: 0222306 (1999-10-01), None
patent: WO 92/03137 (1992-03-01), None
patent: WO 93/05770 (1993-01-01), None
patent: WO 99/63992 (1999-12-01), None
patent: WO 99/64045 (1999-12-01), None
patent: WO 00/02543 (2000-01-01), None
patent: WO 02/060461 (2002-08-01), None
patent: WO 02/096415 (2002-12-01), None
patent: WO 03/097045 (2003-11-01), None
patent: WO 03/097067 (2003-11-01), None
patent: WO 03/097098 (2003-11-01), None
patent: WO 2004/034963 (2004-04-01), None
patent: WO 2004/058258 (2004-07-01), None
Maxwelli et al., “Calcium-channel blockers and cognitive function in ederly people: results from the Canadian Study of Health and Aging.”CMAJ161(5):501-506, 1999.
Meredith and Elliot, “Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences.”J Hypertens22:1641-1648, 2004.
Yamada et al., “Alterations in calcium antagonist receptors and calcium content in senescent brain and attenuation by nimodipine and nicardipine.”JRET277:721-727, 1996.
Prof. Dr. med. Michael Strupp, Recent treatment studies in Alzheimer's disease, MS, cluster headache, focal cortical dysplasia and ALS, J Neurol 251:1546-1548, (2004).
McGreer, Patrick L. and Edith G. McGreer, “Inflammation of the brain in Alzheimer's disease: implications for therapy,” Journal of Leukocyte Biology, Apr. 1999, vol. 65: 409-415.
Nilsson, Lars N. G., et al., “Alpha-1-Antichymotrypsin Promotes Beta-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease,” The Journal of Neuroscience, Mar. 2001, 21(5):1444-1451.
Mullan Michael J.
Paris Daniel
Alzheimer's Institute of America, Inc.
Bryan Cave LLP
Kim Jennifer M
LandOfFree
Method for reducing amyloid deposition, amyloid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing amyloid deposition, amyloid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing amyloid deposition, amyloid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225780